Selvita profile image

Ryvu Therapeutics

WSE: RVU

PLN710.7m market cap

PLN44.5 last close

Ryvu Therapeutics is an oncology R&D company. The two most advanced assets in clinical development are SEL24, a dual PIM/FLT3 inhibitor out-licensed to Menarini Group, and wholly owned SEL120, a selective CDK8 inhibitor. Ryvu also has a diversified preclinical R&D pipeline.

Investment summary

In March 2020, Ryvu announced its partner Menarini Group (via subsidiary Berlin-Chemie) has successfully completed the dose-escalation part (Phase I) of the ongoing Phase I/II study with SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor in a Phase I/II trial for acute myeloid leukaemia (AML). The recommended dose for the Phase II part of the study (cohort expansion) has been established. Ryvu is a pure biotech, so the ongoing turbulence in the global markets has a limited effect on the outlook of the company in our view. Moreover, Ryvu is financed until 2021, which positions it well to weather the volatility. Our valuation is unchanged at PLN1.08bn or PLN67.4/share.

Y/E Sep
Revenue (PLNm)
EBITDA (PLNm)
PBT (PLNm)
EPS (gr)
P/E (x)
P/CF (x)
2018A 24.2 N/A 9.2 33.0 134.8 N/A
2019A 25.8 N/A (34.1) (213.0) N/A N/A
2020E N/A N/A N/A N/A N/A N/A
2021E N/A N/A N/A N/A N/A N/A
Industry outlook

The profiles of SEL24 and SEL120 are potentially unique compared to existing clinical-stage competitors and both candidates may offer efficacy advantages.

Last updated on 31/03/2020
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (PLNm) 98.1
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 4.5 (1.1) 20.4
Relative* 22.1 40.5 84.0
52-week high/low 51.2gr/30.1gr
*% relative to local index
Key management
Paweł Przewięźlikowski CEO

Content on Ryvu Therapeutics